3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trialCarel W. le Roux, Aila Rissanen, Rafael Violante Ortíz et al.|The Lancet|2017Cited by 843
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J.L. Heerspink, Chris Vercammen, Hans‐Henrik Parving et al.|The Lancet|2019Cited by 609
Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic controlUrsula Barnas, Gert Mayer, Alice Schmidt et al.|Diabetologia|1997Cited by 65